CLOV 1D - Health Is Back in Trend

Oct 31

On the daily chart, Clover Health (CLOV) has broken out of its descending channel and triangle, now pulling back for a retest near 3.27–3.43 - a key buy zone aligned with the MA50. Buyers are clearly regaining control, and the setup looks ready for continuation.

Technically:

– first clean breakout of the downtrend since January 2025;
– volume expansion on bullish candles, suggesting institutional accumulation;
– holding above the former resistance turned support.

Upside targets: $4.71 (local volume peak) and $5.98, offering +70% potential upside if momentum sustains.

From a fundamental perspective, Clover Health is stabilizing its business:

– a leading player in Medicare Advantage, with an expanding senior member base;
– Q3 results show 40% reduction in net loss and +18% YoY revenue growth;
– leveraging AI-driven healthcare analytics to improve efficiency and patient outcomes;
– with high short interest, a confirmed breakout above $4.70 could ignite a short squeeze.

Tactical plan: accumulation near 3.27–3.43, add above 4.70, targets 4.71 → 5.98. Sometimes the healthiest trend is the bullish one.

Dec 5

Trade active

CLOV: I'm starting to accumulate. The potential is too great to ignore.

Clover Health is back in focus. Yes, the third quarter was disappointing due to high medical expenses, causing the stock to fall by 30%. But it is precisely these moments that create strong entry points.

The company is approaching a key turning point. I expect Clover to achieve sustainable GAAP profitability for the first time in 2026. The market has already begun to factor this into its expectations. Clover Assistant is growing, customer retention has improved, and the revenue structure has become more stable.

My target for the end of 2026 is around $5.76. This represents more than 130% potential growth from current levels.
I am starting to build a position in advance while big money is also entering the asset.